ASCO Direct™ Highlights: 2022 Official Annual Meeting Review

Seattle, WA US
June 18, 2022 to June 19, 2022

This CME-accredited oncology conference, ASCO Direct™ Highlights: 2022 Official Annual Meeting Review, is designed to improve the care of cancer patients by educating clinicians involved in cancer care.  

This oncology conference features some of the most well-known experts in the field of hematology and oncology who will provide a comprehensive overview of noteworthy data presented at the 2022 ASCO Annual Meeting (ASCO2022) in June of 2022. The program includes in-depth discussion and analysis of the latest scientific findings and practice-changing advances in the field and a scientific abstract session. Expert faculty will place abstract findings from ASCO2022 into clinical context and discuss how the results may change the current standard of care. 

Target Audience

  • Medical oncologists
  • Radiation oncologists
  • Surgical oncologists
  • Oncology residents/fellows
  • Oncology NPs/PAs
  • Oncology pharmacists
  • Oncology nurses 

Learning Objectives

At the conclusion of the activity, participants will be able to:

  • Discuss new and updated treatment options for patients with hematologic malignancies and solid tumors
  • Identify side effects, indications, and contra-indications of therapies used to diagnose and treat cancers
  • Explain how to effectively manage side-effects associated with cancer treatment
  • Review abstracts presented at ASCO® 2022 and discuss their application in clinical settings
Course summary
Available credit: 
  • 11.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.
Course opens: 
11/24/2021
Course expires: 
12/01/2022
Event starts: 
06/18/2022 - 6:30am PDT
Event ends: 
06/19/2022 - 4:00pm PDT
Cost:
$1.00
Add to calendar: 

Conference Chairs: Shailender Bhatia, MD and Petros Grivas, MD, PhD

Day 1

All times below are listed in Pacific Standard Time (PST).

07:00 – 08:00 AM: Registration
08:00 AM – 09:30 AM: Hematologic malignancies session

Moderator: Dr. David Aboulafia

08:00 - 08:30 AM: MDS/leukemias - Dr. Anna Halpern

08:30 - 09:00 AM: Multiple myeloma - Dr. Shaji Kumar

09:00 - 09:30 AM: Lymphoma & CLL - Dr. Ryan Lynch

9:30 – 10:00 AM: Break/Exhibits/Innovation Theater

Innovation Theater - Sponsored by Amgen, Inc.

“Measurable Residual Disease in B-Cell Acute Lymphoblastic Leukemia: State of the Art” with Ryan Cassaday, MD of University of Washington & Fred Hutchinson Cancer Center

Location – Portland B (same floor)

Disclaimer - This program is not part of the CME activity.

10:00 – 12:00 PM: Thoracic oncology session

Moderator: Dr. Joseph Rosales

10:00 - 10:30 AM: Early-stage lung cancer - Dr. Christina Baik

10:30 - 11:00 AM: Targeted therapies in lung cancer - Dr. Jack West

11:00 - 11:30 AM: Immunotherapy in lung cancer - Dr. Rafael Santana-Davila

11:30- 12:00 PM: Covid-19: Implication for cancer care - Dr. Dimpy Shah

12: 00 – 13:00 PM: Lunch/Break/Innovation Theater

Innovation Theater - Sponsored by Bristol Myers Squibb.

“Treatment Options for Patients with Resectable and Metastatic Non-Small Cell Lung Cancer” with Ani Balmanoukian, MD of The Angeles Clinic and Research Institute.

Location – Portland B (same floor)

Disclaimer - This program is not part of the CME activity.

 

Innovation Theater - Sponsored by Exelixis, Inc.

"An Exelixis Product for the Clinical Management of HCC". Speaker - Munveer Bhangoo, MD

Location – Discovery B (same floor)

Disclaimer - This program is not part of the CME activity.

13:00 – 15:00 PM: General Oncology session

Moderator: Nikhil Kamat, MD

13:00 - 13:30 PM: Sarcoma updates - Dr. Michael Wagner

13:30 - 14:00 PM: Brain tumor updates - Dr. Vyshak Venur

14:00 - 14:30 PM: Head neck cancer - Dr. Ezra Cohen

14:30 - 15:00 PM: Gynecologic cancer - Dr. Kalyan Banda

15:00 – 15:30 Break
15:30 – 17:00 PM: Genitourinary cancer session

Moderator: Dr. Jessica Hawley

15:30 - 16:00 PM: Prostate cancer - Dr. Evan Yu

16:00 - 16:30 PM: Bladder cancer - Dr. Petros Grivas

16:30 - 17:00 PM: Kidney cancer - Dr. Scott Tykodi

Day 2

07:00 – 08:00 AM: Registration and Breakfast
08:00 – 09:00 AM: Skin cancer

Moderator: Dr. Kelly Paulson

08:00 - 08:30 AM: Melanoma update - Dr. Shailender Bhatia

08:30 - 09:00 AM: Non-melanoma skin cancers - Dr. Evan Hall

9:00 to 10:30 AM: GI cancer session

Moderator: Dr. Petros Grivas

09:00 - 09:30 AM: Colorectal cancer - Dr. G. Weldon Gilcrease

09:30 - 10:00 AM: Hepatobiliary malignancies - Dr. Daneng Li

10:00 - 10:30 AM: Other GI cancers - Dr. David Zhen

10:30 to 10:45 AM: Break
10:45 to 12:15 PM: Breast cancer session

Moderator: Dr. Tanya Wahl

10:45 - 11:15 AM: Early-stage breast cancer - Dr. Poorni Manohar

11:15 - 11:45 AM: Metastatic breast cancer 1 (hormone receptor positive) - Dr. Hope Rugo

11:45 - 12:15 PM: Metastatic breast cancer 2 (HER2 +ve and triple negative breast cancer) - Dr. Mark Pegram

Grand Hyatt Seattle
721 Pine St
Seattle, WA 98101
United States
Booking Link

HOTEL ROOM RESERVATION

A limited number of rooms have been reserved for the attendees of this conference at the Grand Hyatt Seattle at the discounted rates listed below. All reservations must be made by Friday, May 27, 2022 to receive the discounted rate. Please follow the link below to reserve your room: https://www.hyatt.com/en-US/group-booking/SEAGH/G-ASCO

Name changes on, or other transfers of, room reservations will not be accepted after the Cut-Off Date. The Guest Room Rates are quoted exclusive of any applicable taxes taxes (which are currently 15.7% and $2 nightly Seattle Tourism Assessment Fee) applicable service fees, and/or Hotel-specific fees in effect at the time of the Event. 

Grand Hyatt Seattle is located conveniently in downtown Seattle within walking distance to Space Needle, Pike Place Market, and the shopping district. Take advantage of public transportation when you stay at the Grand Hyatt.
 

TRAVEL

Grand Hyatt Seattle is located conveniently in downtown Seattle within walking distance to Space Needle, Pike Place Market, and the shopping district. Take advantage of public transportation when you stay at the Grand Hyatt.
 

TRANSPORTATION
Distance from Seattle-Tacoma International Airport: 15 miles.

The following transportation options are available from/to the airport.

  • Taxi – 25 minutes (estimated $50.00 each way)
  • Scheduled Airport Shuttles – 30 minutes (estimated $35.00 each way)
  • Uber/Lyft – 25 minutes (estimated $30.00 each way)
  • Link Light Rail – 40 minutes ($3.00 each way) - *Exit at Westlake Station, Grand Hyatt is 2 blocks southwest.

PARKING
The hotel offers convenient parking for guests and visitors. The hotel parking options include valet or self parking:
• Valet Parking: $55/night; No In & Out privileges included
• Self-Parking: $37/night; No In & Out privileges included

You can also self park at the nearby Hyatt Regency at $18/night with in/out privileges included.

Identification and mitigation of potential conflict of interests:

All relevant financial relationships have been identified and mitigated for all individuals in control of content for this accredited continuing education activity.

 

PLANNING COMMITTEE DISCLOSURE STATEMENT:

None of the members of the planning committee, nor any member of their immediate families, have a relevant financial interest in or affiliation with any commercial supporter of this educational activity and/or with the manufacturer(s) of commercial products and/or providers of any commercial services discussed in this educational activity.

 

Glynn Weldon Gilcrease, MD has no relevant financial relationships to disclose at this time.

Kalyan Banda, MD has no relevant financial relationships to disclose at this time.

Petros Grivas, MD, PHD has a financial relationship (Independent contractor) with Merck, Bristol-Myers Squibb, AstraZeneca, EMD Serono, Seattle Genetics, Pfizer, Janssen, Mirati Therapeutics, Exelixis, Roche, Genentech, Dyania Health, Infinity Pharmaceuticals, QED Therapeutics, 4D Pharma PLC, Regeneron Pharmaceuticals, Astellas Pharma, Guardant Health, Urogen pharma, Gilead Sciences, Silverback Therapeutics; financial relationship (Grant or Contract) with Research funding to the institution: Pfizer, Clovis Oncology, Bavarian Nordic, Bristol-Myers Squibb, Debiopharm Group, Merck, QED Therapeutics, GlaxoSmithKline, Mirati Therapeutics, EMD Serono, G1 Therapeutics, Gilead Sciences.

Vyshak Venur, MD has a financial relationship (Independent contractor) with Seagen.


Scott Tykodi, MD, PhD has a financial relationship (Independent contractor) with Exelixis; financial relationship (Independent contractor) with Merck; financial relationship (Independent contractor) with Bristol Myers Squibb; financial relationship (Independent contractor) with Intellisphere, LLC; financial relationship (Grant Or Contract) with Bristol Myers Squibb; financial relationship (Grant Or Contract) with Genentech; financial relationship (Grant Or Contract) with Pfizer; financial relationship (Grant Or Contract) with Nektar Therapeutics; financial relationship (Grant Or Contract) with Merck; financial relationship (Grant Or Contract) with Exelixis; financial relationship (Grant Or Contract) with Jounce Therapeutics.

Speaker/Topic Presenter(s)

Christina Baik, MD MPH

has a financial relationship (Grant Or Contract) with Blueprint Medicines;.
has a financial relationship (Grant Or Contract) with Guardant;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Grant Or Contract) with Turning Point;.
has a financial relationship (Grant Or Contract) with Takeda;.
has a financial relationship (Grant Or Contract) with Daiichi Sankyo;.

Ezra Cohen

has a financial relationship (Independent contractor) with MSD;.
has a financial relationship (Independent contractor) with Ayala;.
has a financial relationship (Independent contractor) with Kinnate Biopharma;.
has a financial relationship (Independent contractor) with Hoopika;.
has a financial relationship (Independent contractor) with Kahr Medical;.
has a financial relationship (Independent contractor) with Mirati;.
has a financial relationship (Independent contractor) with Roche;.
has a financial relationship (Independent contractor) with Psioxus Therapeutics;.
has a financial relationship (Independent contractor) with Eisai;.
has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Pangea Therapeutics;.
has a financial relationship (Independent contractor) with NCCN;.
has a financial relationship (Stock) with Primmune Therapeutics;.
has a financial relationship (Independent contractor) with Cel Sci;.
has a financial relationship (Independent contractor) with Istari;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Nectin Tx;.
has a financial relationship (Independent contractor) with Kura;.
has a financial relationship (Stock) with Kinnate Biopharma;.
has a financial relationship (Independent contractor) with Axelia;.
has a financial relationship (Independent contractor) with ImmunoSensor;.
has a financial relationship (Independent contractor) with Mana Therapeutics;.

Evan Hall, MD, MPhil

has a financial relationship (Other) with Nektar;.
has a financial relationship (Other) with Bristol-Myers-Squibb;.
has a financial relationship (Other) with Replimune;.
has a financial relationship (Other) with NiKang;.
has a financial relationship (Other) with ImCheck;.

Anna Halpern, MD

has a financial relationship (Other) with Imago Biosciences;.
has a financial relationship (Professional Services) with Agios Pharmaceuticals;.
has a financial relationship (Other) with Jazz pharmaceuticals;.
has a financial relationship (Other) with Incytes Pharmaceuticals;.
has a financial relationship (Professional Services) with Notable Labs;.
has a financial relationship (Other) with Bayer;.
has a financial relationship (Other) with Karyopharm Therapeutics;.
has a financial relationship (Professional Services) with Abbvie;.
has a financial relationship (Other) with Gilead Sciences;.

Shaji Kumar, MD

has a financial relationship (Professional Services) with Consulting/Advisory Board participation: (with no personal payments) Abbvie, Amgen, BMS, Janssen,  Roche-Genentech, Takeda, Astra-Zeneca, Bluebird Bio, Epizyme, Secure Biotherapeutics and (with personal payment) Oncopeptides, Beigene, Antengene ;.
has a financial relationship (Grant Or Contract) with Research funding for clinical trials to the institution: Abbvie, Amgen, BMS, Carsgen,  Janssen,  ,  Astra-Zeneca, Novartis, Roche-Genentech,  Takeda, Tenebio, Molecular Templates;.

Daneng Li

has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with TerSera Therapeutics;.
has a financial relationship (Independent contractor) with Eisai;.
has a financial relationship (Independent contractor) with Ipsen;.
has a financial relationship (Independent contractor) with Coherus;.
has a financial relationship (Independent contractor) with Adagene;.
has a financial relationship (Independent contractor) with Genentech;.
has a financial relationship (Independent contractor) with Servier;.
has a financial relationship (Grant Or Contract) with Brooklyn ImmunoTherapeutics;.
has a financial relationship (Independent contractor) with QED;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Independent contractor) with Exelixis;.

Ryan Lynch

has a financial relationship (Grant Or Contract) with Juno Therapeutics;.
has a financial relationship (Grant Or Contract) with Genentech;.
has a financial relationship (Grant Or Contract) with TG Therapeutics;.
has a financial relationship (Grant Or Contract) with Cyteir;.
has a financial relationship (Grant Or Contract) with Bayer;.
has a financial relationship (Grant Or Contract) with Incyte;.
has a financial relationship (Other) with Morphosys;.
has a financial relationship (Grant Or Contract) with RAPT;.
has a financial relationship (Grant Or Contract) with SeaGen;.

Poorni Manohar, MD

has no relevant financial relationships to disclose at this time.

Mark Pegram, MD

has no relevant financial relationships to disclose at this time.

Hope Rugo

has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Daiichi;.
has a financial relationship (Grant Or Contract) with Boehringer Ingelheim;.
has a financial relationship (Grant Or Contract) with Gilead;.
has a financial relationship (Grant Or Contract) with Pfizer;.
has a financial relationship (Grant Or Contract) with Roche ;.
has a financial relationship (Grant Or Contract) with Sermonix;.
has a financial relationship (Grant Or Contract) with Ayala;.
has a financial relationship (Professional Services) with NAPO;.
has a financial relationship (Grant Or Contract) with Lilly;.
has a financial relationship (Grant Or Contract) with Macrogenics;.
has a financial relationship (Grant Or Contract) with AstraZeneca;.
has a financial relationship (Professional Services) with Samsung;.
has a financial relationship (Grant Or Contract) with Novartis;.
has a financial relationship (Grant Or Contract) with Seattle Genetics;.
has a financial relationship (Grant Or Contract) with Polyphor;.
has a financial relationship (Professional Services) with Puma;.

Rafael Santana-Davila, MD

has no relevant financial relationships to disclose at this time.

Dimpy Shah, MD, PhD

has no relevant financial relationships to disclose at this time.

Michael Wagner, M.D.

has a financial relationship (Independent contractor) with Epizyme;.
has a financial relationship (Independent contractor) with Deciphera;.
has a financial relationship (Independent contractor) with Adaptimmune;.

Howard (Jack) West, MD, Associate Professor, City of Hope Cancer Center, Los Angeles, CA

has a financial relationship (Independent contractor) with Mirati;.
has a financial relationship (Independent contractor) with Merck;.
has a financial relationship (Independent contractor) with Genentech/Roche;.
has a financial relationship (Independent contractor) with Takeda;.
has a financial relationship (Independent contractor) with AstraZeneca;.
has a financial relationship (Independent contractor) with Regeneron;.

Evan Yu, Professor of Medicine, University of Washington

has a financial relationship (Independent contractor) with Janssen;.
has a financial relationship (Independent contractor) with Exelixis;.
has a financial relationship (Independent contractor) with Bayer;.
has a financial relationship (Independent contractor) with Advanced Accelerator Applications;.
has a financial relationship (Independent contractor) with Merck;.

David Zhen, MD

has a financial relationship (Grant Or Contract) with Daiichi-Sankyo;.
has a financial relationship (Grant Or Contract) with SeaGen;.
has a financial relationship (Grant Or Contract) with Merck;.
has a financial relationship (Grant Or Contract) with Astra Zeneca;.
Moderator(s)

David Aboulafia, MD

has no relevant financial relationships to disclose at this time.

Jessica Hawley, MD, MS

has a financial relationship (Grant Or Contract) with Regeneron;.
has a financial relationship (Grant Or Contract) with Dendreon;.
has a financial relationship (Independent contractor) with Seagen;.

Nikhil Kamat, Clinical Assistant Professor, Hematology/Oncology UW/NWH

has no relevant financial relationships to disclose at this time.

Kelly Paulson, MD, PhD

has no relevant financial relationships to disclose at this time.

Joseph Rosales, MD

has no relevant financial relationships to disclose at this time.

Tanya Wahl, Medical Oncologist, Medical Director Providence Swedish Cancer Institute Issaquah

has no relevant financial relationships to disclose at this time.
has no relevant financial relationships to disclose at this time.

Fengting Yan, MD

has no relevant financial relationships to disclose at this time.

Commercial Support Acknowledgment:

This activity is supported with independent medical education grants from the following companies:

  • Jazz Pharmaceuticals
  • Seagen, Inc.
  • Exact Sciences

 

Available Credit

  • 11.00 ABIM MOC II
    Successful completion of this CME activity, which includes participation in the evaluation component, enables the participant to earn up to 11.00 Medical Knowledge points in the American Board of Medicine's (ABIM) Maintenance of Certification (MOC) program. Participants will earn MOC points equivalent to the amount of CME credits claimed for the activity. It is the CME activity provider's responsibility to submit participant completion information to ACCME for the purpose of granting ABIM MOC credit.
  • 11.00 AMA PRA Category 1 Credit™
    The Binaytara Foundation is accredited by the Washington State Medical Association to provide continuing medical education for physicians. The Binaytara Foundation designates this live activity for a maximum of 11.00 AMA PRA Category 1 Credit™. Physicians should claim only the credit commensurate with the extent of their participation in the activity. This activity meets the criteria for up to 11.00 hours of Category I CME credit to satisfy the relicensure requirements of the Washington State Medical Quality Assurance Commission.
  • 11.00 Nursing Contact Hours
    Provider approved by the California Board of Registered Nursing, Provider # CEP17035, for 11.00 Contact Hours.

 

 

 

Price

Cost:
$1.00
Please login or register to take this course.

Late Registration Fees (starting 6/01/22)

Physicians (non-industry) - $450

Non-physician HCP (non-industry) - $300

Industry representatives - $950

NOTICE TO HCPS EMPLOYED BY THE INDUSTRY:

If you are employed by industry, including pharmaceuticals and biotech companies, you must pay the INDUSTRY REGISTRATION FEE to participate in any meeting organized by the Binaytara Foundation. If you misrepresented yourself as a healthcare provider not employed by the industry and failed to pay the Industry registration fee, the following fees apply:

  • If your company has purchased a display table at the event, you will be billed the full INDUSTRY REGISTRATION FEE plus a fine equivalent to the full industry registration fee for that event = 2 X the industry registration fee.
  • If your company has NOT purchased a display table at the event AND you attended the meeting without paying a full industry registration fee, you will be billed a full GENERAL DISPLAY FEE for that event. 

Any outstanding display fee, registration fee, and fines must be paid before the industry employee or the company will be able to attend/display at our conferences again.

Cancellation Policy

You may cancel your enrollment at any time. Cancellation fees apply as below:

  • 50% of the paid registration fee will be refunded if registration is cancelled six weeks before the conference.
  • No refunds will be issued if registration is cancelled after that date.  

No credits will be offered if you do not complete all required steps of this activity which include registration, participation in the live activity, and completion of pre & post tests as well as course evaluations.